Antibiotic resistance of pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-Year Period

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Yayan, Josef ^a   Ghebremedhin, Beniam ^a   Rasche, Kurt ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; GERMANY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNIVERSITY HOSPITAL; CROSS INFECTION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTION; TRANSMISSION;

AGED; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GERMANY; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84947212530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139836     Document Type: Article

References (43)

1. de Bentzmann S, Plésiat P. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ. Microbiol. 2011; 13: 1655-1665. doi: 10.1111/j.1462-2920.2011.02469.x PMID: 21450006
2. Hardalo C, Edberg SC. Pseudomonas aeruginosa: assessment of risk from drinking water. Crit. Rev. Microbiol. 1997; 23: 47-75. PMID: 9097014
3. Mena KD, Gerba CP. Risk assessment of Pseudomonas aeruginosa in water. Rev Environ Contam. Toxicol. 2009 201, 71-115. doi: 10.1007/978-1-4419-0032-6-3 PMID: 19484589
4. Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-Associated infections and antimicrobial use. Euro Surveill. 2012; 17: 20316. PMID: 23171822
5. Kollef MH, Chastre J, Fagon JY, François B, Niederman MS, Rello J, et al. Global prospective epidemiologic and surveillance study of ventilator-Associated pneumonia due to Pseudomonas aeruginosa. Crit. Care Med. 2014; 42:2178-87. doi: 10.1097/CCM.0000000000000510 PMID: 25054674
6. Bubonja-Sonje M, Matovina M, Skrobonja I, Bedenic B, Abram M. Mechanisms of Carbapenem Resistance in Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa from a Croatian Hospital. Microb Drug Resist. 2015; [Epub ahead of print].
7. Tran CS, Rangel SM, Almblad H, Kierbel A, Givskov M, Tolker-Nielsen T, et al. The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier. PLoS Pathog. 2014; 10: e1004479. doi: 10.1371/journal.ppat.1004479 PMID: 25375398
8. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug. Resist. Updat. 2000; 3: 247-255. PMID: 11498392
9. Akter S, Shamsuzzaman SM, Jahan F. Community acquired bacterial pneumonia: aetiology, laboratory detection and antibiotic susceptibility pattern. Malays. J. Pathol. 2014; 36: 97-103. PMID: 25194532
10. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 2006; 50: 43-48. PMID: 16377665
11. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-Acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754. PMID: 11401897
12. Watkins RR, Lemonovich TL. Diagnosis and management of community-Acquired pneumonia in adults. Am. Fam. Physician. 2011; 83: 1299-1306. PMID: 21661712
13. World Health Organization (WHO). International Classification of Diseases (ICD). Available: http://www.who.int/classification/icd/en/. Accessed 23 January 2015.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Available: http://clsi.org/blog/2012/01/13/clsi-publishes-2012-Antimicrobialsusceptibility-testing-standards/. Accessed 23 January 2015.
15. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints 2011-2014. Available: http://www.eucast.org. Accessed 23 January 2015.
16. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 1966; 45: 493-496. PMID: 5325707
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18: 268-281. doi: 10.1111/j. 1469-0691.2011.03570.x PMID: 21793988
18. Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med. 1987; 8, 119-134. PMID: 3552385
19. Pseudosel™Agar (Cetrimide Agar). Available: http://www.bd.com/ds/productCenter/297882.asp. Accessed 23 January 2015.
20. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 2008; 46: 1069-1077. doi: 10.1086/527442 PMID: 18444827
21. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit. Care Med. 2009; 37: 1463-1469. doi: 10.1097/CCM.0b013e31819ced02 PMID: 19242341
22. Tan TY, Ng SY. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med. J. 2006; 47: 621-624. PMID: 16810437
23. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob. Agents Chemother. 2009; 53: 4924-4926. doi: 10. 1128/AAC.00786-09 PMID: 19704135
24. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 2008; 14: 816-827. doi: 10.1111/j. 1469-0691.2008.02061.x PMID: 18844682
25. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest. 2011; 139: 909-919. doi: 10.1378/chest.10-0166 PMID: 21467058
26. Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-Acquired pneumonia. Expert Rev Anti Infect Ther. 2010; 8:505-514. doi: 10.1586/eri.10.35 PMID: 20455679
27. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven ?-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014; 58: 6844-6850. doi: 10.1128/AAC.03681-14 PMID: 25182652
28. Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents. 2010; 36: 513-522. doi: 10.1016/j.ijantimicag.2010.08.005 PMID: 20926262
29. Lodise TP Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44: 357-363 PMID: 17205441
30. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008; 46: 862-867. doi: 10.1086/528712 PMID: 18279040
31. Farajzadeh Sheikh A, Rostami S, Jolodar A, Tabatabaiefar MA, Khorvash F, Saki A, et al. Detection of metallo-beta lactamases among carbapenem-resistant Pseudomonas aeruginosa. Jundishapur J Microbiol. 2014; 7: e12289. doi: 10.5812/jjm.12289 PMID: 25774271
32. Somayaji R, Parkins MD. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis. Ther Deliv. 2015; 6: 121-137. doi: 10.4155/tde.14.94 PMID: 25690082
33. Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, et al. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother. 2015; 59: 2315-2327. doi: 10.1128/AAC.04099-14 PMID: 25645838
34. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 50: 2626-2631. PMID: 16870751
35. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003) Diagn Microbiol Infect Dis. 2005; 52: 265-273. PMID: 16105569
36. Kotwal A, Biswas D, Kakati B, Thakuria B, Bhardwaj N. Efficacy of anti-pseudomonal antibiotics: need to reconsider the empirical use of cefepime. Indian J Med Res. 2014; 140: 560-562. PMID: 25488453
37. Chaudhary M, Shrivastava SM, Varughese L, Sehgal R. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr Clin Pharmacol. 2008; 3:118-122. PMID: 18700304
38. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 441-451. doi: 10.1586/erp.10.49 PMID: 20715920
39. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006; 55: 1619-1629. PMID: 17108263
40. Pappas G, Saplaoura K, Falagas ME. Current treatment of pseudomonal infections in the elderly. Drugs Aging. 2009; 26: 363-79. doi: 10.2165/00002512-200926050-00001 PMID: 19552489
41. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-Acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-Analysis. Antimicrob Resist Infect Control. 2014; 3:32. doi: 10.1186/2047-2994-3-32 PMID: 25371812
42. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006; 50: 43-8. PMID: 16377665
43. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-Acquired pneumonia. Eur Respir J. 2008; 32: 726-32. doi: 10.1183/09031936.00003608 PMID: 18508833